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RESEARCH IN CONTEXT 39 
 40 
Evidence before this study: Consumer digital health applications are proliferating worldwide 41 
yet there remains little scientific evidence of effectiveness. At the same time, cardiovascular 42 
disease is increasing and use of digital health strategies in primary care offer a potential 43 
opportunity to reduce the disease burden. Some digital health research has explored outcomes 44 
related to individual risk factors, stand-alone apps and, text messaging systems, but none have 45 
reported a large-scale randomized controlled trial in primary care where the digital health 46 
intervention is electronically integrated between the consumer and electronic health record. 47 
 48 
Added value of this study: This is a large and robust study (n=934), with 1-year follow-up, 49 
where the effectiveness of an integrated digital health intervention is assessed and the potential 50 
value of the interactive system for consumers is detailed. 51 
 52 
Implications of all the available evidence: The integrated and consumer-focused digital health 53 
intervention has the potential to be effective in increasing physical activity levels and ehealth 54 
literacy and may also lead to small improvements in other cardiovascular risk factors. To 55 
enhance effectiveness of complex and multifaceted interventions, it is likely that implementation 56 
requires a systematic approach that targets the health system, provider and, patient. 57 




ABSTRACT  59 
Background: Although consumer digital health applications (apps) have the potential to 60 
improve health behaviors and outcomes most are not integrated with existing health information 61 
systems. We aimed to examine the effectiveness of a consumer web-based app linked to primary 62 
care electronic health records (EHRs). 63 
 64 
Methods: Multicenter, open-label, randomized controlled trial involving patients with or at risk 65 
of cardiovascular disease (CVD) recruited from Australian primary care. Intervention 66 
participants received an interactive app which was pre-populated and refreshed with EHR risk 67 
factor data, diagnoses and, medications. Interactive risk calculators, motivational messages and 68 
lifestyle goal tracking were also included. Control group received usual health care. Primary 69 
outcome was adherence to guideline-recommended medications (≥80% of days covered for 70 
blood pressure (BP) and statin medications). Secondary outcomes included attainment of risk 71 
factor targets and eHealth literacy. The trial was registered at the Australian New Zealand 72 
Clinical Trials Registry (ACTRN12613000715774). 73 
 74 
Findings: Total of 934 patient were recruited (intervention, n=486 and control, n=448); mean 75 
age 67.6 (±8.1) years, 76.7% male. At 12 months, the proportion with >80% days covered with 76 
recommended medicines was low overall and there was no difference between intervention and 77 
control groups (32.8% vs 29.9%; relative risk [RR] 1.07 [95% CI, 0.88-1.20] p=0.49). There was 78 
borderline improvement in the proportion meeting BP and LDL targets in intervention vs control 79 
(17.1% vs 12.1% RR 1.40 [95% CI, 0.97–2.03] p=0.07). The intervention was associated with 80 
increased attainment of physical activity targets (87.0% intervention vs 79.7% control, p=0.02) 81 
and e-health literacy scores (72.6% intervention vs 64.0% control, p=0.02). 82 
 83 
Interpretation: A consumer app integrated with primary health care EHRs was not effective in 84 
increasing medication adherence. Borderline improvements in risk factors and modest behavior 85 
changes were observed. To enhance effectiveness of such interventions, it is likely multifaceted 86 
strategies targeting health system, provider and, patient are needed. 87 
 88 
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Cardiovascular disease (CVD) is responsible for most of the global burden of non-communicable 92 
diseases (NCD) accounting for over 17 million deaths globally in 2016.1 Internationally, 93 
guidelines place adherence to prevention medication and, healthy lifestyle behaviors at the core 94 
of CVD risk management, primary and secondary prevention recommendations.2, 3 However, use 95 
of evidence-based medications and lifestyle change are typically suboptimal4 and with an aging 96 
population the health burden is escalating. Thus, implementation of primary and secondary 97 
prevention strategies (such as healthy living, adherence to medicines) are an international 98 
priority requiring development and testing of innovative and scalable strategies that are 99 
evidence-based and better support patients.5 100 
 101 
Major advances in internet and mobile technology over the past decade provide potential 102 
solutions to reduce the burden of CVD and broaden the reach of health care. Worldwide, more 103 
than five billion people own mobile phones6 and opportunities to deliver healthcare digitally are 104 
expanding exponentially with strategies such as internet portals, data-driven precision medicine 105 
and smartphone applications (apps).7 Although scientific evidence of their effectiveness is 106 
growing, research lags behind the rapid emergence and adoption of technology innovations 107 
targeting health-related behaviors. Benefits of interactive internet portals have been 108 
demonstrated in managing chronic conditions.8 Our randomized controlled trial (RCT) found a 109 
physician-focused decision support tool to be effective in increasing CVD risk assessment when 110 
embedded within the primary care clinical record system.9 In particular, personalized risk score 111 
information that is explained on a visually interesting interface, can make the impact of 112 
improving biometric risk factor values (for example, blood pressure), or behaviours (for 113 
example, smoking cessation), more compelling.9 Hypothesized as a useful springboard to more 114 
engagement by patients with CVD risk factor control, the concept was adapted to a consumer-115 
facing resource in the current trial. Other trials have demonstrated the benefits of apps for 116 
improving medication adherence10 and text messages for cardiovascular risk reduction.11 117 
However, to the best of our knowledge these interventions are almost all stand-alone where data 118 
is entered into the system manually and they are not integrated with the patient’s electronic 119 
health record. 120 
 121 
Despite the potential for access to one’s electronic health record (EHR) to increase and improve 122 
consumer engagement with disease prevention actions, relatively little is known about the 123 
effectiveness of such interventions for risk factor control. Personal EHRs now form a core 124 
component of many national health reform strategies12 but often stand-alone from consumer-125 
controlled devices or applications. In the Australian primary care setting, EHRs offer software 126 
systems that assist clinicians with drug prescribing, referrals, coordination of care, clinical 127 
coding, billing, quality improvement activities and, reporting.13 According to a recent American 128 
survey, over two-thirds of adults over 55 years of age own a smartphone and over 85% use the 129 
internet with the numbers are increasing annually.14 As such, use of EHRs to auto-populate 130 
consumer-focused digital health interventions has promise, but robust evidence is not available 131 
about effectiveness in reducing CVD risk. Therefore, the aim of this study was to evaluate the 132 
effect of a consumer-focused digital health intervention, integrated with each participant’s 133 
primary care EHR, on guideline-recommended medication adherence, cardiovascular risk factor 134 







Study design and participants 139 
The Consumer Navigation of Electronic Cardiovascular Tools (CONNECT) study was a 140 
parallel-design, single-blind randomized clinical trial enrolling 934 patients with, or at high risk 141 
of, CVD presenting at 23 Australian primary care practices and one Aboriginal Community 142 
Controlled Health Service (ACCHS) with an average follow-up of 12 months (Figure 1). The 143 
protocol is detailed elsewhere.15 Participants in both intervention and control groups received 144 
usual health care, but those in the intervention arm were given access to a web application that 145 
was integrated with their primary health care EHR. Participants provided written informed 146 
consent. Ethical approval was obtained from the University of Sydney Human Research Ethics 147 
Committee (2013/716) and the New South Wales Aboriginal Health and Medical Research 148 
Council (959/13). 149 
 150 
Consenting adult patients (>18 years) with access to the internet at least once a month via mobile 151 
phone, tablet or computer, and at moderate to high risk of a CVD event were eligible to 152 
participate. Participants had to have presented to a participating primary care practice or health 153 
service twice in the last two years and once in the last six months. Moderate to high 154 
cardiovascular risk was defined as having (i) a five year CVD risk ≥10% using the Framingham 155 
risk equation;16 (ii) a clinically high risk condition based on Australian guidelines 156 
(Aboriginal/Torres Strait Islander and age >75 years, diabetes and age>60 years, diabetes and 157 
albuminuria, eGFR<45ml/min, systolic blood pressure (BP) ≥ 180mmHg, diastolic BP ≥ 158 
110mmHg, total cholesterol > 7.5mmol/L) or an established CVD diagnosis (ischemic heart 159 
disease, stroke/transient ischemic attack, peripheral vascular disease).16 Potential participants 160 
with a severe intellectual disability, or insufficient English to provide written, informed consent 161 
were excluded. 162 
 163 
Recruitment 164 
Primary health care services in Sydney, New South Wales, Australia were recruited. Of these, 23 165 
were general practices and one was an ACCHS. Software to enable integration of the EHR with 166 
the consumer portal was installed at each participating site. A reimbursement of AUD$50 per 167 
participant recruited was made to participating practices to support administrative time of 168 
practice staff. All software license costs and technical support were provided free of charge to 169 
the study sites for the duration of the trial. Royal Australian College of General Practitioners 170 
Quality Improvement and Continuing Professional Development points were also offered to 171 
participating General Practitioners (GPs) to support their professional development requirements 172 
in terms of contributing to research and quality improvement. 173 
 174 
Recruitment took place between November 2014 and May 2017 (follow-up until July 2018). 175 
Potential participants who met attendance and clinical eligibility criteria were initially identified 176 
by study personnel using a data extraction tool routinely used in Australian primary health care 177 
software systems. Once identified, the list of potential participants was reviewed by the attending 178 
GP to identify unsuitable patients. All others were then mailed a study invitation letter from their 179 
GP and received a follow-up telephone call from study personnel. During the phone call, 180 
eligibility including internet access were confirmed. If the person was interested in participating, 181 
an in-person appointment at the practice or health service was arranged during which written 182 
informed consent was obtained prior to baseline assessment and randomization. Consent was 183 




Benefits Scheme (MBS), to determine health service utilization and, the Pharmaceutical Benefits 185 
Scheme (PBS), which contains the dispensing data required to ascertain proportion of days 186 
covered with guideline recommended medications. 187 
 188 
Randomization and masking 189 
Participants were randomized to either have access to the CONNECT web application in 190 
addition to their usual health care (intervention) or receive their usual health care without access 191 
to the web-application (control). In both groups, any advice and/or other interventions provided 192 
by the GP/health service continued at their discretion. Randomization was conducted 193 
independently using a central computer-based randomization service with a 1:1 ratio. A 194 
permuted block sequence was used with stratification by practice, baseline CVD risk status and, 195 
Aboriginal/Torres Strait Islander status. The random allocation sequence was concealed from 196 
study personnel, and took place after collection of baseline data. Study personnel taking baseline 197 
and follow-up measurements were blinded to group allocation and participants were asked not to 198 
discuss whether they were receiving the intervention or not during their follow up visit. 199 
 200 
Intervention 201 
The CONNECT digital health intervention was a consumer-focused, responsive web application 202 
with integration of data from the primary health care EHR. It was accessible on any internet-203 
enabled device (smartphone, tablet, laptop or personal computer) and was developed using a 204 
persuasive and user-centered design process.17 Prior to participant recruitment, software was 205 
installed at each participating primary care service to enable upload of selected personal health 206 
data into the patients’ secure portal (Extensia Pty Ltd, Brisbane, Australia). Uploaded data 207 
included medical diagnoses, prescribed medications, physical measurements (weight, waist 208 
circumference and, blood pressure), cholesterol record and hemoglobin A1c (HbA1c) for 209 
diabetic patients. The consumer application has multiple components (Figure 2) to encourage 210 
participants to: (i) use every-day familiar devices to increase understanding of the relationship to 211 
CVD prevention of lifestyle-related behavior, medication adherence and, regular discussion of 212 
these topics with their GP; and (ii) use one or more of self-monitoring, goal setting and, digital 213 
messaging functions to facilitate better adherence to these actions. Registered participants had 214 
access to numerous features that facilitated knowledge, support and, goal-setting in relation to 215 
their personal cardiovascular risk including: 216 
 217 
 An auto-populated list of their current medical conditions and prescribed medications 218 
with links to more detailed information to enhance knowledge. 219 
 A personalized CVD risk score where patients could see the relationship of their risk 220 
factors to the score estimation, then use interactive functionality to visually see the 221 
impact of managing their risk factors on their absolute risk (Figure 2). 222 
 Interactive tools and resources to assist with care navigation; alongside data imported 223 
from their EHR where patients could log additional physical measurements taken at home 224 
and track their progress with, for example, blood pressure control or weight reduction if 225 
relevant. Calendar links also enabled the patient to record due dates for test updates, for 226 
example cholesterol measurement. 227 
 Interactive goal-setting based on healthier eating, physical activity, smoking cessation 228 
and emotional well-being as well as goal achievement tracking with virtual rewards to 229 




 An interactive social media component with which participants could read and/or write 231 
comments, ask questions or share stories that was moderated by trained clinical staff. 232 
 Optional receipt of personalized CVD prevention tips and motivational messages related 233 
to diet, medications and lifestyle via email and/or short message service (SMS) that were 234 
developed using a published process18 and have previously been found to be effective11 235 
and useful for patients19 in improving cardiovascular risk. 236 
 237 
Study personnel supported intervention arm participants over 12 months using standard protocols 238 
to ensure uniformity of support activities and included health professionals with nursing, 239 
dietetics and pharmacy training. Participants were trained in use of the application either in 240 
person or by telephone and provided with a printed reference guide if needed. Thereafter, they 241 
were contacted by telephone and/or email at scheduled intervals: week 2, week 6, week 12 and 242 
week 26. During these routine support calls, staff answered questions, repeated aspects of the 243 
initial training if requested, explained clinical content if needed, and addressed navigation, 244 
function or other software-related issues. All communications were logged by time requirement 245 
and content, and software trouble-shooting was referred to a technical help desk. Participants 246 
could contact research staff by telephone or email whenever they needed additional support. To 247 
ensure blinding of outcome assessments, different personnel supported the intervention 248 
participants to those who conducted the baseline and 12-month assessments. 249 
 250 
Data collection procedures 251 
Primary data were collected at face-to-face assessments at baseline and face-to-face or telephone 252 
assessments at end of study (12 months) by research assistants who were blinded to group 253 
allocation. A Standard Operating Procedure was followed by all research assistants to optimize 254 
uniformity and completeness of data collection and to ensure standardization of physical 255 
measurements and data entry. Data were entered into a case report form and a purpose-built, 256 
secure online database. The software installed at each practice or health service to facilitate 257 
integration of the EHR with the consumer portal also enabled relevant clinical data to be 258 
extracted during the study period. In addition, PBS and MBS data were obtained from the 259 
Australian Government Department of Human Services to assess prescription medications 260 
dispensed. Site monitoring visits were performed periodically to ensure quality documentation, 261 
correct software function, and adherence to various milestones for study personnel contact in the 262 
follow up period for intervention arm participants. 263 
 264 
Outcomes 265 
The primary outcome was the proportion of days covered with guideline recommended 266 
medications at 12 months. This was defined based on the proportion of maximum medication 267 
dispensed from the patient’s pharmacy using national PBS administrative dispensing data. All 268 
medications of interest for this study are processed via this system regardless of the pharmacy 269 
visited. The primary outcome was defined as met if at end of study ≥80% of maximum 270 
medication had been dispensed in the previous 12 months for at least one BP-lowering 271 
medication AND a statin medication. For people with or at high risk of CVD, Australian 272 
guidelines recommend prescription of at least one BP lowering medication and a statin unless 273 
contraindicated.16 People with established cardiovascular disease are additionally recommended 274 
an anti-thrombotic agent (most commonly aspirin) however, because aspirin is usually available 275 
over the counter and is not reliably captured in the national pharmaceutical benefits scheme 276 





Secondary and tertiary outcomes at 12 months included: 279 
 280 
1. The proportion of participants whose BP AND fasting low density lipoprotein (LDL) 281 
cholesterol were meeting Australian guideline targets (defined as: ≤ 130/80mmHg for 282 
CVD, Diabetes or albuminuria or ≤140/90mmHg for all others, AND LDL-cholesterol < 283 
2.0mmol/L).16 284 
2. Proportion meeting individual targets for BP and LDL cholesterol  285 
3. Mean difference in SBP and LDL levels 286 
4. Proportion of days covered with BP lowering medication and statin medication separately 287 
5. Smoking - point abstinence (verified by carbon monoxide meter where CO>8ppm 288 
represents recent tobacco smoking)20 289 
6. Obesity – proportion with a body mass index >30 kg/m2 290 
7. Self-reported physical activity based on World Health Organization (WHO) Global 291 
Physical Activity Questionnaire21 292 
8. Health-related Quality of life – EQ5D (version 5L with Australian standardized 293 
weights)22 294 
9. Fruit and vegetable intake, fish, salt and saturated fat intake – self reported portions 295 
consumed in 7 days prior and compared with published guidelines recommendations23 296 
10. Health Literacy (Health Literacy Questionnaire, HLQ)24 297 
11. e-health literacy (eHealth literacy score, eHEALS) with a threshold score of 26 set as an 298 
estimate of high or low eHealth literacy where higher scores represent better eHealth 299 
literacy 25 300 
12. All-cause mortality (medical records); cardiovascular and renal events, new onset 301 
diabetes (self-report verified by the primary care record) and; hospital admissions (self-302 
report verified by primary care record). 303 
 304 
In our original study protocol the primary outcome was BP and LDL target attainment 305 
(secondary outcome number 1 listed above), however due to our inability to reach the original 306 
recruitment target of 2000 participants, the study steering committee and ethics committee 307 
approved changing this to a secondary outcome and making medication adherence our primary 308 
outcome. This was implemented before end of study data collection commenced. 309 
 310 
Statistical Analyses 311 
Using the pre-randomization baseline rates, we assumed the proportion of people with >80% 312 
coverage with guideline-recommended medications was 28%. A total sample size of 1000 313 
participants, allowing for a 20% loss to follow-up would have 90% power to detect an absolute 314 
improvement of at least 10% using two-sided tests, with p values of less than 0.05 judged as 315 
significant. For the original primary outcome of BP and LDL target attainment, this sample size 316 
provided 80% power to detect a 7% absolute improvement, assuming a baseline control rate of 317 
11%. All statistical analyses were conducted blinded to group allocation. 318 
 319 
A pre-specified statistical analysis plan that was finalized prior to database lock was followed 320 
(Supplement). The analysis was done by an independent statistician using SAS (version 9.3). 321 
Primary analyses were unadjusted, following an intention-to-treat principle and conducted blind 322 
to treatment allocation. Multivariate analyses were performed to adjust for any significant 323 
differences between each study arm. Pre-specified sub-group analyses were conducted to 324 
compare outcomes based on gender, age, baseline, eHealth literacy score and CVD status 325 




groups in terms of relative risks (RR), 95% confidence intervals (CIs) and two-sided p values. 327 
Characteristics were compared between groups using independent t tests for continuous or Χ2 328 
tests for categorical variables. Mann-Whitney U tests were used where data were not normally 329 
distributed. 330 
 331 
Role of the funding source 332 
The funder of the study played no role in study design, data collection, data analysis, data 333 
interpretation, or writing of the report. JR and DP had full access to all the data in the study and 334 
had final responsibility for the decision to submit for publication. 335 
 336 
Data Availability 337 
The data that support the findings of this study are available from the corresponding author upon 338 
reasonable request. 339 
 340 
RESULTS 341 
In total, 7457 potentially eligible patients were identified using the primary care EHR and 3905 342 
were excluded by their GP. We approached 3552 patients, 2618 did not meet eligibility criteria 343 
or declined participation and 934 were enrolled and randomized (Figure 1). At 12-month follow-344 
up 13 participants had withdrawn from the study and 30 did not consent to data linkage to access 345 
pharmacy dispensing data (Figure 1). At baseline, the groups were well matched for 346 
demographics, cardiovascular risk factors and medication prescriptions and the mean age of 347 
participants was 67.6 (±8.1) years, 77% were male and 41% had existing CVD (Table 1). One 348 
third of participants had existing coronary heart disease (33.3%), peripheral arterial disease 349 
(3.6%), chronic kidney disease (3.0%), atrial fibrillation (10.8%), heart failure (1.1%) and a 350 
previous stroke (9.3%). 351 
 352 
Overall, 93% (451/486) of intervention group participants commenced use of the intervention. 353 
Thereafter, participants were classified as non-adopters (no logins after the training session - 354 
13%, 58/451), low-users (at least one login any across any three months of the follow-up period - 355 
47%, 211/451) or high-users (at least one login in any four months of the follow-up period - 40% 356 
182/451). Adherence to guideline recommended medications did not differ significantly between 357 
levels of intervention use (p=0.44). At 12 months, the intervention group had a non-significant 358 
higher proportion of participants achieving the primary outcome of ≥80% medication days covered 359 
than in the control group (32.8% v 29.9%; RR 1.07 [95% CI 0.88-1.20]) (Figure 3). The relative 360 
risk was broadly unchanged when adjusted in multivariate analyses for age, sex and diabetes 361 
status. There were no significant differences between the control and intervention groups on the 362 
primary outcome for any of our pre-specified sub-groups of gender, age, baseline eHealth 363 
literacy score and CVD subgroups (Figure 4)  364 
 365 
At 12 months, there was a borderline improvement in BP and LDL control rates in intervention 366 
vs control (17.1% vs 12.1%, RR 1.41 95% CI 0.98 – 2.03 p=0.07), however control rates 367 
remained low overall in both study arms. There were no significant differences between the 368 
intervention and control groups in mean LDL cholesterol (2.5mmol/L v 2.4 mmol/L, mean 369 
difference -0.08mmol/L, 95% CI -0.22 – 0.05 p=0.24) and SBP (136.3mmHg v136.4mmHg, 370 
mean difference 0.12mmHg, 95% CI -2.21 – 2.45 p=0.92). For lifestyle behaviors, there were 371 
significantly more participants meeting recommended levels for physical activity (87% vs 372 
79.7%, p=0.02) in the intervention than the control group (Figure 3). There were no significant 373 
differences in any of other lifestyle related behaviors including quality of life scores and HLQ 374 




the pre-defined threshold of high e-health literacy in the intervention vs control arm (72.6% vs 376 
64.0%, p=0.016). There were few all-cause hospitalizations (59 vs 54) and deaths (2 vs 1) in both 377 
intervention and control groups respectively. Owing to small numbers significance testing was 378 
not performed. 379 
 380 
DISCUSSION 381 
Among patients with or at high risk of CVD, a consumer-focused and EHR integrated software 382 
application did not improve adherence to guideline recommended medicines. The study 383 
population had low to very low medication adherence rates and concomitant risk factor control 384 
rates at baseline and there was only a marginal improvement post-intervention. The minimal 385 
effects on most outcomes occurred despite reasonable implementation fidelity. The findings are 386 
concerning given this population is at high to very high risk of experiencing either a first or 387 
subsequent CVD event. The evidence base for guideline-recommended treatments (BP-lowering 388 
medications and statins) is well established and when these medications are used in combination 389 
they can lower risk of a CVD event by around 40%.26 Optimal medication use (combined BP and 390 
statin medication coverage for at least 80% of the previous 12-month period) was observed in 391 
only around one third of people with around a half of people taking BP medications consistently 392 
and only 40% taking a statin over a 12-month period. These gaps are well known and in the 393 
Australian primary care context have changed little over the last two decades.  394 
 395 
The adherence literature related to CVD medications has repeatedly show that adherence is 396 
heterogeneously impacted by disease factors, therapy factors, healthcare factors, patient factors 397 
and, social factors.27 As such, strategies to improve adherence tend to have mixed success. The 398 
large treatment gaps identified in our study and the minimal movement with this intervention 399 
suggests more intensive, system wide strategies are needed to address this intractable problem. 400 
Traditionally, intervention approaches look at supply side (provider and system) strategies and 401 
demand side (consumer-focused) strategies. Digital health interventions for cardiovascular risk 402 
are proliferating and effect sizes vary greatly. On the consumer side, the Text2PreventCVD 403 
Collaboration found text messaging systems have modest but potentially important reductions in 404 
cardiovascular risk factors.28 Similarly, supply-side interventions to improve quality include 405 
audit and feedback, decision support tend to show mixed outcomes.29 Patient and provider 406 
education strategies are moderately successful. A recent systematic review of strategies to 407 
increase statin prescribing rates shed some insights on both sides - patient education initiatives 408 
were effective in 4 of 7 trials and two trials that combines electronic decision support with audit 409 
and feedback were effective.30 More recently, behavioral economics studies are emerging but 410 
also inconclusive to date – one recent study used payments to providers and/or patients to 411 
improve adherence rates to statins and found that only the combined provider and patient 412 
incentives were effective in lowering LDL cholesterol and that overall the intervention effects 413 
were modest and not cost-effective.31 414 
 415 
This mixed evidence base suggests that contextual factors at multiple levels - health system, 416 
service, provider, patient, and community levels - play a role in influencing the effectiveness of 417 
these strategies. The recently published Non-adoption, Abandonment, Scale-up, Spread and 418 
Sustainability (NASS) framework provides a mechanism for explicitly assessing complexity 419 
across multiple domains to understand adoption barriers and enablers with technology 420 
interventions.32 Two NASS domains of particular importance in this study was the value 421 
proposition to users and the adopter system. The CONNECT intervention has multidimensional 422 




taking lifestyle actions it may have had little value to users in relation to medication 424 
management. There was also complexity with the adopter system which was attempting to 425 
promote a more engaged discussion between provider and patient by integrating the application 426 
with electronic health record systems. This link was perhaps not sufficiently strong and research 427 
on the impact of direct messaging between patient and providers is an area for greater 428 
exploration. A more detailed examination of the impact on health-related behavior and how the 429 
EHR-linked strategy was received, used, and accepted by patients and providers in this study has 430 
been reported elsewhere.30 431 
 432 
Importantly, in this study there was some misalignment in results in terms of medication 433 
prescription and risk factor measurements and qualitative consumer/patient usefulness and 434 
perceived value. This is a common potential problem for RCTs that have a focus on behavior 435 
change based on complex interventions where there are multiple moving parts.33 Together with 436 
the improvements in self-reported physical activity, our findings suggest there may have been 437 
some value to users for lifestyle changes and motivation. For example, qualitative research 438 
conducted alongside this RCT found that 40% of participants reported using the web-app 439 
improved their mental health and well-being, 47% reported higher physical activity levels and 440 
61% reported healthier eating.34 In addition, the qualitative research found 73% of users reported 441 
benefiting from personalised cardiovascular disease risk score; 69% liked the goal tracking; 52% 442 
benefited from the risk factor self-monitoring and 54% liked the motivational health tips.34 The 443 
observed disparity between objective clinical outcomes and patient preferences is an important 444 
consideration when evaluating this research and future RCTs of complex interventions. Other 445 
studies have also highlighted the importance of relevance of outcome measures to 446 
consumers/patients.35 This is an area that requires further research to help understand how future 447 
studies can ensure emphasis on outcomes that are of high value to patients but are also 448 
scientifically robust so we can most effectively estimate the potential benefits of digital health 449 
interventions that are consumer-directed. 450 
 451 
Study limitations include the following. First, as mentioned in the methods, the study was 452 
originally powered on risk factor control and we were aiming to recruit 2000 individuals. This 453 
resulted in a slight imbalance in numbers in the control and intervention groups although no 454 
major difference in measures. Despite low withdrawal rates, recruitment proved challenging 455 
where primary care practices are not well supported to undertake research. We had to revise the 456 
recruitment target to 1000 patients and a more appropriate primary outcome (prescription of 457 
evidence-based medications). It is possible that given the trend to significance in risk factor 458 
target control that the study was underpowered to show an effect, however, even if such an effect 459 
was observed it would have been modest at best and the broad conclusions remain unchanged. 460 
Second, there was a much higher proportion of men recruited to the study than women. The 461 
reasons for this are complex and are related to both a higher proportion of men identified at high 462 
CVD risk, but also a higher proportion of men than women agreeing to participate in the study. 463 
This is important given the emerging data on gender disparities in both health status but also 464 
health care. Third, the study was conducted in mainly urban primary care practices in one city 465 
and practice level factors may be different in other settings which may lead to different 466 
conclusions. Also, two practices experienced challenges with installing the software to upload 467 
data to the shared electronic health record and this limited the ability of these sites to refresh 468 
information from the patient record into the CONNECT application. Finally, due to the low 469 
numbers of ACCHSs recruited, we are not able to make any scientific conclusions about 470 




study population and hence have not attempted to do so. This would need to be the subject of 472 




A consumer app integrated with primary health care EHRs was not effective in increasing 477 
medication usage in a population at high risk of CVD events with low pre-existing use of 478 
recommended medications. Borderline improvements in risk factor control and modest 479 
behavioral changes were observed. When considering the current evidence of behavior change 480 
strategies for CVD risk reduction, this study affirms that such interventions remain challenging 481 
to implement and to achieve clinical effectiveness. Innovative approaches to intensify the effects 482 
of such interventions are needed and it is likely such approaches need to target multiple levels of 483 
the health system.  484 
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Age, mean (SD) years 66.8 (8.4) 68.4 (7.8) 67.6 (8.1) 
Male, n (%) 368 (75.7) 348 (77.7) 716 (76.7) 
Ethnicity n (%) 
Caucasian 406 (83.5) 396 (88.4) 802 (85.9) 
Asian 22 (4.5) 17 (3.8) 39 (4.2) 
Aboriginal or Torres Strait Islander 27 (5.6) 10 (3.8) 37 (4.0) 
Other 31 (6.4) 25 (5.6) 56 (6.0) 
Education < 12 years, n (%) 15 (3.1) 13 (2.9) 28 (3.0) 
Weekly household income (Australian dollars) n (%) 
$0-799 105 (21.7) 96 (21.4) 201(21.6) 
$800-1999 180 (37.1) 155 (34.6) 335 (35.9) 
>$2000/week 116 (24.0) 119 (26.5) 235 (25.2) 
No response 83 (17.1) 78 (17.4) 161 (17.3) 
Clinical data and risk factors 
High risk of cardiovascular disease, n (%) 285 (58.6) 266 (59.4) 551 (59.0) 
Existing cardiovascular disease, n (%) 201 (41.4) 182 (40.6) 383 (41.0) 
Diabetes 160 (32.9) 111 (24.8) 271 (29.0) 
Mean body mass index (SD) kg/m2 29.9 (5.7) 29.7 (5.1) 29.8 (5.4) 
Body mass index ≥ 30kg/m2, N (%) 205 (42.2) 188 (42.1) 393 (42.1) 
Waist circumference, mean (SD) cm 105.7 (14.9) 106.4 (13.6) 106.0 (14.3) 
Mean systolic blood pressure (SD) mmHg 137.3 (15.9) 139.0 (16.6) 138.1 (16.3) 
Mean diastolic blood pressure (SD) mmHg 78.9 (10.6) 79.8 (10.8) 79.3 (10.7) 
LDL-C, mean (SD) mmol/L 2.6 (1.04) 2.6 (0.98) 2.6 (1.01) 
Meeting target for BP2, n (%) 195 (40.1) 165 (36.8) 360 (38.5) 
LDL-C ≤2mmol/L, n/N (%) 137/438 (31.3) 121/411 (29.4) 258/849 (30.4) 
Meeting BP and LDL target3 n/N (%) 54/438 (12.3) 46/411 (11.2) 100/849 (11.8) 
HbA1c, mean (SD) mmol/mol 7.0 (1.2) 7.1 (1.3) 7.0 (1.3) 
Current smoker, n/N (%) 63/483 (13.0) 57/443 (12.9) 120/926 (13.0) 
Physically inactive, n/N (%) 61/419 (14.6) 62/387 (16.0) 123/806 (15.3) 
Quality of life and health literacy 
eHeals score, mean (SD) 27.0 (6.43) 27.0 (6.41) 27.0 (6.42) 
eHEALS score ≥26, n/N (%) 326/483 (67.5) 287/448 (64.1) 613/931 (65.8) 
EQ5D score/100, mean (SD) 80.1 (13.8) 79.4 (13.8) 79.8 (13.8) 
Self-reported medication use 
Lipid lowering, n/N (%) 259/460 (56.3) 212/431 (49.2) 471/891 (52.9) 
Antihypertensives, n/N (%) 287/460 (62.4) 275/431 (63.8) 562/891 (63.1) 
Antithrombotics, n/N (%) 180/460 (39.1) 183/431 (42.5) 363/891 (40.7) 
≥80% medication days covered, n/N (%) 133/460 (28.9) 122/431 (28.3) 255 (28.6) 
Abbreviations 
N, number of participants in denominator; n= number of participants in the numerator; SD, standard 
deviation; LDL-C, low density lipoprotein cholesterol; HbA1c, Glycated haemoglobin; EQ5D, 
EuroQual 5D 
Notes 
1. denominators are included where the denominator differed from the column total 
2. BP target defined as: ≤ 130/80mmHg for CVD, Diabetes or albuminuria or ≤140/90mmHg for all 
others 
3. LDL-cholesterol target defined as < 2.0mmol/L 
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